Tolerability of carvedilol initiation in heart failure patients

被引：0

作者：

Fowler, M ^{[1
]}

Colucci, W ^{[1
]}

Bristow, M ^{[1
]}

Packer, M ^{[1
]}

Gilbert, E ^{[1
]}

Cohn, J ^{[1
]}

Wu, B ^{[1
]}

Lukas, M ^{[1
]}

Hu, J ^{[1
]}

Kubo, S ^{[1
]}

Hershberger, R ^{[1
]}

Gottlieb, S ^{[1
]}

Pina, I ^{[1
]}

机构：

[1] Stanford Univ, Med Ctr, Div Cardiol, Palo Alto, CA 94304 USA

来源：

XIII WORLD CONGRESS OF CARDIOLOGY: FREE PAPERS | 1998年

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Instituting beta-blockade in heart failure patients can be associated with worsening clinical status or other signs of intolerance. We examined retrospectively the tolerability of initiation in the US Carvedilol Heart Failure Trials Program (NYHA II-IV patients with EF<35% receiving di-goxin. diuretics and/or ACEI) and two US pilot trials(2-7). In the US Program, initial carvedilol dose was 6.25mg in 97% of 1197 patients challenged; 3% began at, and 7% at some point received, 3.125mg bid. During blinded titration (carvedilol, 696; placebo, 398 patients), 78% and 81% reached protocol-specified target dose, with 2% and 1% withdrawn for safety, respectively. Reducing diuretic dose occurred in 8% on carvedilol, but only 3% on placebo. The incidence of increasing diuretic or changing ACE dose, and the duration of titration did not differ. Target carvedilol dose can be successfully reached in most heart failure patients, although adjustment of other medication, especially decreasing diuretic, may be needed.

引用

页码：599 / 603

页数：5